$BDSX
Biodesix Inc

2023 Q2 Form 10-Q Financial Statement

#000095017023021238 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $11.87M $9.056M $6.548M
YoY Change 8.42% 38.3% -77.32%
Cost Of Revenue $3.238M $3.169M $3.235M
YoY Change -18.64% -2.04% -82.24%
Gross Profit $8.634M $5.887M $3.313M
YoY Change 23.87% 77.69% -68.89%
Gross Profit Margin 72.73% 65.01% 50.6%
Selling, General & Admin $16.65M $18.99M $14.49M
YoY Change 9.29% 31.08% 21.46%
% of Gross Profit 192.85% 322.56% 437.28%
Research & Development $2.910M $3.251M $3.206M
YoY Change -13.42% 1.4% -3.46%
% of Gross Profit 33.7% 55.22% 96.77%
Depreciation & Amortization $300.0K $300.0K $400.0K
YoY Change -25.0% -25.0% 33.33%
% of Gross Profit 3.47% 5.1% 12.07%
Operating Expenses $22.80M $25.43M $21.01M
YoY Change 0.99% 21.04% -39.01%
Operating Profit -$10.93M -$16.37M -$14.46M
YoY Change -6.01% 13.22% 159.02%
Interest Expense $2.430M $2.391M $1.137M
YoY Change 2330.0% 110.29% 74.65%
% of Operating Profit
Other Income/Expense, Net -$2.429M -$2.329M -$1.125M
YoY Change -42.14% 107.02% -18.36%
Pretax Income -$13.36M -$18.70M -$15.59M
YoY Change -15.6% 19.99% 123.94%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.36M -$18.70M -$15.59M
YoY Change -15.6% 19.99% 123.9%
Net Earnings / Revenue -112.5% -206.52% -238.03%
Basic Earnings Per Share -$0.17 -$0.24 -$0.50
Diluted Earnings Per Share -$0.17 -$0.24 -$501.6K
COMMON SHARES
Basic Shares Outstanding 78.46M 77.97M 31.31M
Diluted Shares Outstanding 78.51M 77.77M 31.07M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.41M $25.28M $16.43M
YoY Change -26.19% 53.86% -70.29%
Cash & Equivalents $17.41M $25.28M $16.40M
Short-Term Investments
Other Short-Term Assets $3.717M $4.608M $7.032M
YoY Change -38.25% -34.47% -6.24%
Inventory
Prepaid Expenses
Receivables $4.119M $4.901M $3.774M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $25.25M $34.78M $27.23M
YoY Change -27.99% 27.73% -66.46%
LONG-TERM ASSETS
Property, Plant & Equipment $19.00M $13.10M $4.028M
YoY Change 380.91% 225.15% 18.93%
Goodwill $15.03M $15.03M $15.03M
YoY Change 0.0% 0.0%
Intangibles $8.871M $9.311M $11.13M
YoY Change -17.0% -16.35% -13.18%
Long-Term Investments
YoY Change
Other Assets $6.988M $6.376M $2.009M
YoY Change 350.55% 217.37% -33.03%
Total Long-Term Assets $52.38M $46.01M $34.42M
YoY Change 30.38% 33.68% 0.34%
TOTAL ASSETS
Total Short-Term Assets $25.25M $34.78M $27.23M
Total Long-Term Assets $52.38M $46.01M $34.42M
Total Assets $77.62M $80.79M $61.65M
YoY Change 3.18% 31.05% -46.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.501M $1.563M $2.120M
YoY Change 95.48% -26.27% -42.7%
Accrued Expenses $6.981M $5.740M $6.173M
YoY Change 4.71% -7.01% -15.0%
Deferred Revenue $1.100M $1.100M $2.500M
YoY Change -50.0% -56.0% 4.17%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $50.00K $50.00K $51.00K
YoY Change -99.58% -1.96% -98.11%
Total Short-Term Liabilities $27.95M $22.10M $29.81M
YoY Change -15.49% -25.87% 84.89%
LONG-TERM LIABILITIES
Long-Term Debt $24.66M $25.08M $10.06M
YoY Change 186.85% 149.47% -66.82%
Other Long-Term Liabilities $896.0K $648.0K $615.0K
YoY Change 1180.0% 5.37% -63.54%
Total Long-Term Liabilities $56.67M $54.15M $24.06M
YoY Change 64.32% 125.05% -61.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.95M $22.10M $29.81M
Total Long-Term Liabilities $56.67M $54.15M $24.06M
Total Liabilities $84.62M $76.24M $53.87M
YoY Change 25.25% 41.53% -31.86%
SHAREHOLDERS EQUITY
Retained Earnings -$399.5M -$386.1M -$317.6M
YoY Change 19.83% 21.59% 19.48%
Common Stock $79.00K $78.00K $32.00K
YoY Change 97.5% 143.75% 18.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.993M $4.550M $7.781M
YoY Change
Total Liabilities & Shareholders Equity $77.62M $80.79M $61.65M
YoY Change 3.18% 31.05% -46.62%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$13.36M -$18.70M -$15.59M
YoY Change -15.6% 19.99% 123.9%
Depreciation, Depletion And Amortization $300.0K $300.0K $400.0K
YoY Change -25.0% -25.0% 33.33%
Cash From Operating Activities $937.0K -$7.686M -$13.10M
YoY Change -109.77% -41.32% 15.65%
INVESTING ACTIVITIES
Capital Expenditures $6.472M $7.676M $262.0K
YoY Change -1803.16% 2829.77% -43.78%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.472M -$7.706M -$352.0K
YoY Change 1603.16% 2089.2% -31.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.599M
YoY Change
Debt Paid & Issued, Net $12.00K $11.00K
YoY Change 9.09% -99.96%
Cash From Financing Activities -2.330M -2.421M -2.834M
YoY Change -110.53% -14.57% -157.24%
NET CHANGE
Cash From Operating Activities 937.0K -7.686M -13.10M
Cash From Investing Activities -6.472M -7.706M -352.0K
Cash From Financing Activities -2.330M -2.421M -2.834M
Net Change In Cash -7.865M -17.81M -16.29M
YoY Change -164.68% 9.38% 136.32%
FREE CASH FLOW
Cash From Operating Activities $937.0K -$7.686M -$13.10M
Capital Expenditures $6.472M $7.676M $262.0K
Free Cash Flow -$5.535M -$15.36M -$13.36M
YoY Change -39.93% 14.98% 13.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsCurrent
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsCurrent
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001439725
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39659
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BIODESIX, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3986492
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2970 Wilderness Place,
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
CY2023Q1 dei City Area Code
CityAreaCode
303
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
417-0500
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
BDSX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78457943
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25275000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43088000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
200000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
118000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4901000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5065000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
4608000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5181000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
34784000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
53334000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13097000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5848000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9311000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9797000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2194000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2973000
CY2023Q1 us-gaap Goodwill
Goodwill
15031000
CY2022Q4 us-gaap Goodwill
Goodwill
15031000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6376000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5923000
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
46009000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
39572000
CY2023Q1 us-gaap Assets
Assets
80793000
CY2022Q4 us-gaap Assets
Assets
92906000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1563000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1685000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5740000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8218000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1133000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
962000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1762000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1543000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
11706000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
10341000
CY2023Q1 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
50000
CY2022Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
49000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
41000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22098000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22839000
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
25084000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25004000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12039000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5254000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
16374000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
18645000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
648000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
558000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
54145000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
49461000
CY2023Q1 us-gaap Liabilities
Liabilities
76243000
CY2022Q4 us-gaap Liabilities
Liabilities
72300000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77979376
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77979376
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77614358
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77614358
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
78000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
390594000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
387948000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-386122000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367420000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4550000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80793000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92906000
CY2023Q1 us-gaap Revenues
Revenues
9056000
CY2022Q1 us-gaap Revenues
Revenues
6548000
CY2023Q1 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
3169000
CY2022Q1 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
3235000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3251000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3206000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18989000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14487000
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
20000
CY2022Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
81000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
25429000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
21009000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16373000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14461000
CY2023Q1 us-gaap Interest Expense
InterestExpense
2391000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1137000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-61000
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
12000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2329000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1125000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18702000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15586000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77765000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77765000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31070000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31070000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-61000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2281000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18702000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4550000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19727000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1417000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
202000
CY2022Q1 bdsx Stock Issued During Period Values For Deferred Offering Costs
StockIssuedDuringPeriodValuesForDeferredOfferingCosts
600000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1346000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15586000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7781000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-18702000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-15586000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
785000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
908000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
760000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
280000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2281000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1346000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-61000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
198000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-39000
CY2023Q1 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
1357000
CY2022Q1 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
1006000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
30000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
379000
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
20000
CY2022Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
81000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
33000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
78000
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-544000
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
166000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
10000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-466000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2031000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1304000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
129000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-124000
CY2023Q1 bdsx Tenant Improvement Allowances Received
TenantImprovementAllowancesReceived
7248000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-201000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-268000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7686000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13099000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7676000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
262000
CY2023Q1 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
30000
CY2022Q1 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
90000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7706000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-352000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1599000
CY2023Q1 bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
420000
CY2022Q1 bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
202000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2000000
CY2022Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
4625000
CY2022Q1 bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
103000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
12000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
11000
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
801000
CY2022Q1 bdsx Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
30000
CY2022Q1 bdsx Payment Of Equity Financing Costs
PaymentOfEquityFinancingCosts
141000
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-34000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-6000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2421000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2834000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17813000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16285000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43174000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32798000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25361000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16513000
CY2022Q1 bdsx Common Stock Issued For Deferred Offering Costs
CommonStockIssuedForDeferredOfferingCosts
600000
CY2022Q1 bdsx Deferred Offering Costs Amortized Against Additional Paid In Capital
DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital
18000
CY2022Q1 bdsx Debt Issuance Costs Included In Accounts Payable And Other Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
85000
CY2023Q1 bdsx Equity Financing Costs Included In Accounts Payable And Other Accrued Liabilities
EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
61000
CY2022Q1 bdsx Equity Financing Costs Included In Accounts Payable And Other Accrued Liabilities
EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
24000
CY2022Q1 bdsx Operating Lease Right Of Use Assets Obtained In Exchange For Lease Liabilities At Adoption Of Asc842
OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842
1269000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
43000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1228000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
329000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
123000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1032000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
223000
CY2023Q1 bdsx Number Of Cancer Test
NumberOfCancerTest
5
CY2023Q1 bdsx Number Of Commercial Blood Based Test
NumberOfCommercialBloodBasedTest
2
CY2023Q1 bdsx Number Of Sars Co V2 Test
NumberOfSARSCoV2Test
3
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company’s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of March 31, 2023 and December 31, 2022, see Note 9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> – Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
400000
CY2023Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
CY2023Q1 us-gaap Customer Funds
CustomerFunds
5000000.0
CY2022Q4 us-gaap Customer Funds
CustomerFunds
5000000.0
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9311000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18894000
CY2022Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
9097000
CY2023Q1 bdsx Interest Expense Due To Passage Of Time And Fixed Payment Schedule
InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
1100000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20405000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12866000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7308000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7018000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13097000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5848000
CY2023Q1 us-gaap Depreciation
Depreciation
300000
CY2022Q1 us-gaap Depreciation
Depreciation
400000
CY2023Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18903000
CY2023Q1 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
9592000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9797000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1483000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1969000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1963000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1949000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
998000
CY2023Q1 bdsx Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter
835000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9197000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3088000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4671000
CY2023Q1 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
1177000
CY2022Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
1232000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1475000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2315000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5740000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8218000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4981000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5074000
CY2023Q1 us-gaap Notes Payable
NotesPayable
25134000
CY2022Q4 us-gaap Notes Payable
NotesPayable
25053000
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
50000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
49000
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
25084000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25004000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
37000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
50000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
21000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
30000000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
30115000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y4M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.114
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2165000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2084000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3710000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3978000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4063000
CY2023Q1 bdsx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
32264000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48264000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23388000
CY2023Q1 bdsx Lessee Operating Lease Liability Amount Representing Tenant Improvement Allowances
LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances
11075000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
13801000
CY2023Q1 bdsx Tenant Improvement Allowances Expected To Be Received
TenantImprovementAllowancesExpectedToBeReceived
11100000
CY2023Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
CY2023Q1 bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
9000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.73
CY2023Q1 us-gaap Revenues
Revenues
9056000
CY2022Q1 us-gaap Revenues
Revenues
6548000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1000000.0
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
200000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1100000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
10597
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2281000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1346000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2541000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1489000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
344000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.97
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
72000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.38
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2804000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.66
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1007000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1617000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.43
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
805000
CY2023Q1 bdsx Description Of Offering Period Under Plan
DescriptionOfOfferingPeriodUnderPlan
ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
269846
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
476301
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18702000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15586000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77765000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77765000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31070000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31070000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12628000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4695000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0

Files In Submission

Name View Source Status
0000950170-23-021238-index-headers.html Edgar Link pending
0000950170-23-021238-index.html Edgar Link pending
0000950170-23-021238.txt Edgar Link pending
0000950170-23-021238-xbrl.zip Edgar Link pending
bdsx-20230331.htm Edgar Link pending
bdsx-20230331.xsd Edgar Link pending
bdsx-ex10_1.htm Edgar Link pending
bdsx-ex10_2.htm Edgar Link pending
bdsx-ex10_3.htm Edgar Link pending
bdsx-ex31_1.htm Edgar Link pending
bdsx-ex31_2.htm Edgar Link pending
bdsx-ex32_1.htm Edgar Link pending
bdsx-ex32_2.htm Edgar Link pending
bdsx-ex4_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
bdsx-20230331_cal.xml Edgar Link unprocessable
bdsx-20230331_def.xml Edgar Link unprocessable
bdsx-20230331_lab.xml Edgar Link unprocessable
bdsx-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bdsx-20230331_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending